drug · small molecule

RECARBRIO

updated 5mo ago

by $MRK Merck & Co., Inc.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 2

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 1 investigational indication.

targets

Dipeptidase 1

all catalysts(0)

nothing on the calendar yet

Trials studying RECARBRIO

phase3A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute Pyelonephritisactive not recruitingn=579
phase2A Trial of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute Pyelonephritisunknownn=126

News(1)

STAT+: Merck discontinues a crucial antibiotic despite concerns over superbug resistance
Merck discontinued Recarbio, an important antibiotic in the U.S., despite concerns over resistance to superbugs.
stat · 2d ago

brand

RECARBRIO

trade names

Cilastatin sodium component of mk-7655a, Cilastatin sodium component of primaxin, Cilastatin sodium component of recarbrio

generic

CILASTATIN SODIUM

MOA

12.1 Mechanism of Action RECARBRIO is an antibacterial drug [see Microbiology (12.4) ].

indication

1 INDICATIONS AND USAGE RECARBRIO is a combination of imipenem, a penem antibacterial, cilastatin, a renal dehydropeptidase inhibitor, and relebactam, a beta-lactamase inhibitor, indicated in adult and pediatric patients weighing at least 2 kg for the treatment of the following infections caused by susceptible gram-negative microorganisms: Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP). ( 1.1 ) Complicated urinary tract infections, including pyelonephritis (cUTI) in patients who have limited or no alternative treatment options. ( 1.2 ) Complicated intra-abdominal infections (cIAI) in patients who have limited or no alternative treatment options. ( 1.3 ) Approval of the cUTI and cIAI indications is based on limited clinical safety and efficacy data for RECARBRIO. ( 1.2 , 1.3 , 14 ) Limitations of Use RECARBRIO is not recommended in pediatric patients less than 37 weeks post-menstrual age (gestational age at birth plus post-natal age). ( 1.4 , 2.2 ). RECARBRIO is not recommended in pediatric patients weighing less than 30 kg with renal impairment. ( 1.4 , 2.3 ). Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of RECARBRIO and other antibacterial drugs, RECARBRIO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.5 ) 1.1 Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) RECARBRIO ® is indicated in adult and pediatric patients weighing at least 2 kg for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, caused by the following susceptible gram-negative microorganisms: Acinetobacter calcoaceticus-baumannii complex, Enterobacter cloacae , Escherichia coli , Haemophilus influenzae , Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Pseudomonas aeruginosa, and

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 5h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

RECARBRIO

updated 5mo ago

by $MRK Merck & Co., Inc.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 2

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 1 investigational indication.

targets

Dipeptidase 1

all catalysts(0)

nothing on the calendar yet

Trials studying RECARBRIO

phase3A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute Pyelonephritisactive not recruitingn=579
phase2A Trial of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute Pyelonephritisunknownn=126

News(1)

STAT+: Merck discontinues a crucial antibiotic despite concerns over superbug resistance
Merck discontinued Recarbio, an important antibiotic in the U.S., despite concerns over resistance to superbugs.
stat · 2d ago

brand

RECARBRIO

trade names

Cilastatin sodium component of mk-7655a, Cilastatin sodium component of primaxin, Cilastatin sodium component of recarbrio

generic

CILASTATIN SODIUM

MOA

12.1 Mechanism of Action RECARBRIO is an antibacterial drug [see Microbiology (12.4) ].

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 5h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

RECARBRIO

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying RECARBRIO

News(1)

Report a data issue

comments(0)

RECARBRIO

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying RECARBRIO

News(1)

Report a data issue

comments(0)